VYNE Therapeutics Inc.
VYNEDrugs in Pipeline
18
Phase 3 Programs
5
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
FMX103 minocycline foam 1.5%
Facial Papulopustular Rosacea
5mg Serlopitant Tablets
Pruritus
FMX101
Acne Vulgaris
FMX103 1.5%
Papulopustular Rosacea
FMX-101, 4% minocycline foam
Acne Vulgaris
serlopitant
Prurigo Nodularis
5 mg Serlopitant Tablets
Pruritus
VYN201 Gel
Non-segmental Vitiligo
FMX114
Atopic Dermatitis
FMX-103 1.5%
Rosacea
Serlopitant Tablet
Epidermolysis Bullosa
ARK-E021 5%
Acne Vulgaris
Serlopitant High Dose
Pruritus
FDX104 (4% Doxycycline)
Rash Due to Epidermal Growth Factor Receptor Inhibitors
3% Minocycline Foam
Acne Vulgaris
VPD-737
Chronic Pruritus
MK0594
Urinary Incontinence
Topical Minocycline Foam FXFM244
Acne Vulgaris
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FMX103 minocycline foam 1.5% | Phase 3 | Facial Papulopustular Rosacea | - | - |
5mg Serlopitant Tablets | Phase 3 | Pruritus | - | - |
FMX101 | Phase 3 | Acne Vulgaris | - | - |
FMX103 1.5% | Phase 3 | Papulopustular Rosacea | - | - |
FMX-101, 4% minocycline foam | Phase 3 | Acne Vulgaris | - | - |
serlopitant | Phase 2 | Prurigo Nodularis | - | - |
5 mg Serlopitant Tablets | Phase 2 | Pruritus | - | - |
VYN201 Gel | Phase 2 | Non-segmental Vitiligo | - | - |
FMX114 | Phase 2 | Atopic Dermatitis | - | - |
FMX-103 1.5% | Phase 2 | Rosacea | - | - |
Serlopitant Tablet | Phase 2 | Epidermolysis Bullosa | - | - |
ARK-E021 5% | Phase 2 | Acne Vulgaris | - | - |
Serlopitant High Dose | Phase 2 | Pruritus | - | - |
FDX104 (4% Doxycycline) | Phase 2 | Rash Due to Epidermal Growth Factor Receptor Inhibitors | - | - |
3% Minocycline Foam | Phase 2 | Acne Vulgaris | - | - |
VPD-737 | Phase 2 | Chronic Pruritus | - | - |
MK0594 | Phase 2 | Urinary Incontinence | - | - |
Topical Minocycline Foam FXFM244 | Phase 2 | Acne Vulgaris | - | - |
Acne Vulgaris
5 drugs in this indication
Pruritus
5 drugs in this indication
Prurigo Nodularis
1 drug in this indication
Chronic Pruritus
1 drug in this indication
Papulopustular Rosacea
1 drug in this indication
Rosacea
1 drug in this indication
Facial Papulopustular Rosacea
1 drug in this indication
Atopic Dermatitis
1 drug in this indication
Non-segmental Vitiligo
1 drug in this indication
Urinary Incontinence
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in VYNE Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 18 drug candidates in VYNE Therapeutics Inc.'s (VYNE) pipeline across Phase 3, Phase 2. Its lead program is FMX103 minocycline foam 1.5% (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is VYNE Therapeutics Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for VYNE Therapeutics Inc. (VYNE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track VYNE biotech catalysts?→
Add VYNE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow VYNE Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.